Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

AIMS: Exenatide is a glucagon-like peptide-1 receptor agonist shown to improve glycaemic control in patients with type 2 diabetes (T2DM). Intermittent exenatide exposure is achieved with the twice-daily formulation (ExBID), while the once-weekly formulation (ExQW) provides continuous exenatide expos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridge, T, Moretto, T, MacConell, L, Pencek, R, Han, J, Schulteis, C, Porter, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533770/
https://www.ncbi.nlm.nih.gov/pubmed/22734440
http://dx.doi.org/10.1111/j.1463-1326.2012.01639.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533770/
https://www.ncbi.nlm.nih.gov/pubmed/22734440
http://dx.doi.org/10.1111/j.1463-1326.2012.01639.x

Ejemplares similares